Telix Pharmaceuticals shares rose approximately 5% this week. The U.S. Food and Drug Administration (FDA) is expected to announce a decision on the Pixclara brain-cancer imaging agent by September 11.
This submission represents the company's second attempt at approval. The FDA rejected the initial application in 2025 while requesting additional evidence.
Pixclara is a PET scan dye that helps physicians identify recurring aggressive brain tumors. Current imaging methods often struggle to distinguish recurrence from other medical issues.
An approval would provide Telix with its third commercial imaging product and a new revenue stream. The company excluded potential Pixclara sales from its 2026 financial guidance, meaning a positive decision offers upside to current forecasts.